Parathyroid Hormone-Related Peptide (PTHrP) Secretion by Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Clinical Features, Diagnosis, Management, and Follow-Up

Kamp, Kimberly; Feelders, Richard A; Adrichem, Roxanne C. S. van; Rijke, Yolanda B. de; Nederveen, Francien H. van; Kwekkeboom, Dik J.; Herder, Wouter W. de

doi:10.1210/jc.2014-1315

Cited by 56 publications

(47 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In refractory cases, intravenous etomidate has successfully been used but requires intensive monitoring [57] . Hypersecretion of parathyroid hormone-related peptide by metastatic NET seems to be exclusively associated with metastatic pancreatic NET and has a major clinical impact because poorly controllable hypercalcemia is associated with increased morbidity and mortality [58] . In such cases and other more rare syndromes, early diagnosis and management are essential [54] .…”

Section: Syndromes Related To Ectopic Hormonal Secretionmentioning

confidence: 99%

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors

et al. 2017

Self Cite

View full text Add to dashboard Cite

Neuroendocrine tumors of the small intestine are the most common causes of the carcinoid syndrome. Carcinoid heart disease occurs in more than half of the patients with the carcinoid syndrome. Patients with carcinoid heart disease who need to undergo surgery should also undergo preoperative evaluation by an expert cardiologist. Treatment with long-acting somatostatin analogs aims at controlling the excessive hormonal output and symptoms related to the carcinoid syndrome and at preventing a carcinoid crisis during interventions. Patients with a gastrinoma require pre- and postoperative treatment with high doses of proton pump inhibitors. Patients with a glucagonoma require somatostatin analog treatment and nutritional supplementation. Patients with a VIPoma also require somatostatin analog treatment and intravenous fluid and electrolyte therapy. Insulinoma patients generally require intravenous glucose infusion prior to operation. In patients with localized operable insulinoma, somatostatin analog infusion should only be considered after the effect of this therapy has been electively studied.

show abstract

Section: Syndromes Related To Ectopic Hormonal Secretionmentioning

confidence: 99%

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another interesting aspect in our case was the control of tumor secretion of PTHrP provided by everolimus, even at the time of clear radiological progression. PTHrP-producing NETs are rare and some reports have shown limited-time control of hypercalcemia with somatostatin analogs, radiolabeled agents and even sunitinib [10]. An anti-secretory activity of everolimus in patients with insulinomas [11] and carcinoid syndrome [12] has been reported, but we are unaware of other reports of everolimus successfully controlling malignant hypercalcemia related to PTHrP-producing NET.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Long-Term Safety of Everolimus in Pancreatic Neuroendocrine Tumor Associated with Multiple Endocrine Neoplasia Type I: Case Report

2016

View full text Add to dashboard Cite

Background: Approximately 10% of pancreatic neuroendocrine tumors (NET) are associated with familial syndromes, with the most common type being multiple endocrine neoplasia type 1 (MEN-1). However, the available evidence on how to treat NET comes from studies in sporadic NET. Case Report: Here we report the case of a 51-year-old male patient with a metastatic MEN-1-associated pancreatic NET and hypercalcemia related to primary hyperparathyroidism and tumor-secreted parathyroid-related protein. The patient was treated with everolimus, and showed complete resolution of hypercalcemia and tumor control for 3 years when he presented with pulmonary cryptococcosis and disease progression. Conclusion: This case report describes the activity of everolimus in a patient with MEN-1-associated pancreatic NET, its efficacy in treating malignant hypercalcemia associated with NET and the risk of opportunistic infections with prolonged use of this agent.

show abstract

“…Because of the death of these mice at birth the role of PTHrP in the physiology of islets is not known. Neuroendocrine tumors secreting PTHrP resulting in hypercalcemia has been described [76,78].…”

Section: Pthrp and The Pancreasmentioning

confidence: 99%

Parathyroid Hormone Related Peptide (PTHrP): A Mini-Review

Naafs¹

2017

EMIJ

View full text Add to dashboard Cite

In this mini-review the role of parathyroid hormone-related peptide (PTHrP) in physiology and pathophysiology is discussed. Evolving from an unknown humoral factor in the HHM (Hypercalcemia of malignancy) syndrome its role as a "masterregulator" in the PTH family following identification is reviewed. PTHrP has more paracrine and autocrine functions in virtually all tissues than classical endocrine functions and is essential in embryonic, fetal and post-natal life. The physiological functions are near endless. The development of PTH/PTHrP receptor antagonist and agonists has been difficult and disappointing. Its role as a possible cytokine itself and as a regulatory thermogenesis factor in brown adipose tissue in cancer cachexia is discussed. PTHrP assays must be improved for PTHrP to be a reliable biomarker in oncology and to resolve the function of local proteolytic PTHrP fragments which are largely a mystery until now.

show abstract

Parathyroid Hormone-Related Peptide (PTHrP) Secretion by Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Clinical Features, Diagnosis, Management, and Follow-Up

Cited by 56 publications

References 47 publications

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors

Efficacy and Long-Term Safety of Everolimus in Pancreatic Neuroendocrine Tumor Associated with Multiple Endocrine Neoplasia Type I: Case Report

Parathyroid Hormone Related Peptide (PTHrP): A Mini-Review

Contact Info

Product

Resources

About